EGFR and lung adenocarcinoma: The transition from biomarker discovery toward direct genomic characterization of actionable mutations was exemplified by the first investigation of somatic mutation detection in EBC, where the EGFR T790M resistance mutation was successfully identified in patients with stage IV EGFR-positive lung adenocarcinoma.